CervoMed Inc
CRVO
查看詳細走勢圖
7.600USD
-0.300-3.80%
收盤 12/19, 16:00（美東）報價延遲15分鐘
70.32M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-3.80%
5天
-10.06%
1月
-14.41%
6月
+10.95%
今年開始到現在
+224.79%
1年
+240.81%
查看詳細走勢圖
TradingKey CervoMed Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
CervoMed Inc當前公司基本面數據相對非常健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名160/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價22.43。中期看，股價處於平穩狀態。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
CervoMed Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
7
分析師
買入
評級
22.429
目標均價
+155.16%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
CervoMed Inc亮點
亮點風險
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
業績增長期
公司處於發展階段，最新年度總收入9.74M美元
估值合理
公司最新PE估值-2.62，處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉，最新持倉343.46K股
活躍度降低
近期活躍度降低，過去20天平均換手率-0.81
CervoMed Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
CervoMed Inc簡介
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
公司代碼CRVO
公司CervoMed Inc
CEOAlam (John J)
網址https://cervomed.com/
常見問題
CervoMed Inc(CRVO)的當前股價是多少？
CervoMed Inc(CRVO)的當前股價是 7.600。
CervoMed Inc 的股票代碼是什麼？
CervoMed Inc的股票代碼是CRVO。
CervoMed Inc股票的52週最高點是多少？
CervoMed Inc股票的52週最高點是16.940。
CervoMed Inc股票的52週最低點是多少？
CervoMed Inc股票的52週最低點是1.920。
CervoMed Inc的市值是多少？
CervoMed Inc的市值是70.32M。
CervoMed Inc的淨利潤是多少？
CervoMed Inc的淨利潤為-16.29M。
現在CervoMed Inc(CRVO)的股票是買入、持有還是賣出？
根據分析師評級，CervoMed Inc(CRVO)的總體評級為買入，目標價格為22.429。
CervoMed Inc(CRVO)股票的每股收益（EPS TTM）是多少
CervoMed Inc(CRVO)股票的每股收益（EPS TTM）是-2.903。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
